Best Fit Health/Biotechnology Funds ETFs
U.S. News evaluated 29 Health/Biotechnology Funds ETFs and 14 make our Best Fit list. Our list highlights the best passively managed funds for long-term investors. Rankings are assigned based on comparisons with Best Fit funds in this category.
| Best Fit Scorecard | |
|---|---|
| Costs | Good |
| Tracking Error | Good |
| Bid/Ask Ratio | Good |
| Holdings Diversity | Typical |
Fund Description
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors US Listed Pharmaceutical 25 Index (the "Pharmaceutical Index"). The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Fund Snapshot Updated 05.23.2013
| Previous Close | $47.31 | Expense Ratio | 0.35% |
| YTD Return | 20.2% | Avg. 30-Day Volume | 84,337 |
| 1-Year Return | 32.7% | Market Cap | Loading... |
| Bid | $47.37 | Shares Outstanding | 5,338,000 |
| Ask | $47.38 | Dividends | $3.47 |
| Top 10 Holdings | |
|---|---|
| Johnson & Johnson (JNJ) | 12.03% |
| Pfizer Inc (PFE) | 10.33% |
| Novartis A G (NVS) | 8.68% |
| Merck & Co Inc New (MRK) | 7.06% |
| Sanofi (SNY) | 6.22% |
| Glaxosmithkline Plc (GSK) | 6.07% |
| Bristol Myers Squibb Co (BMY) | 5.14% |
| Abbvie Inc (ABBV) | 5.10% |
| Astrazeneca Plc (AZN) | 4.70% |
| Abbott Labs (ABT) | 4.52% |
| % of Total Holdings | 69.80% |
